Cernostics Inc.’s $2.7 million fundraising round is almost complete. The company’s sale of of equity and options is just $100,000 short of its goal, according to a regulatory filing.
The newly re-christened Cernostics (previously known as Cernostics Pathology Inc.) was spun off from Pittsburgh-based Cellumen Inc. At the time of the spinoff, Cernostics’ aim was to focus on "digital imaging pathology and personalized medicine."
Digital pathology is a computerized, image-based environment that enables pathologists to manage and interpret information generated from a digitized glass slide, with image quality comparable to a microscope, according to Advanced Imaging Magazine. The technology aims to make pathologists more productive by allowing them to more easily view, share and archive tissue samples.
The fund-raise comes from five investors–a small number considering that the minimum amount accepted per investor was $7,500, according to the filing.
Cernostics apparently doesn’t have a website, but does have Facebook and Twitter accounts, though no tweets have been sent out from the account. The phone number listed on the filing was Cellumen’s office number. Cernostics company officials didn’t return a call.
Michel Nederlof, Cernostics’ co-founder, president and chief technology officer, was also a co-founder of Cellumen.
